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Abstract
Purpose Existing drug safety systems with phase II and III
studies and post-marketing surveillance by principle do not
allow for the recognition of an important class of adverse
drug reactions (ADRs). ADRs that are resistant to being
detected reliably may a) appear as if they are age-related
chronic diseases, which also manifest themselves in a high
degree without drug treatment, b) arise in “old” drugs, c)
arise during long-term application, and d) arise with the
administration to frail and aged populations.
Conclusions “Silent” and multi-factorial health problems
evolving from long-term drug treatment must therefore be
addressed with a systematic search strategy, as a third track
along with the phase II and III studies and spontaneous
reporting systems which still exist.
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Existing pharmacovigilance system and its limitations
The path to our drug surveillance system has been a thorny
one [1]. In the USA, the FDA was only allowed to demand
safety documentation of drugs after 1938, and it wasn’t until
1962 that manufacturers could be required to prove the
effectiveness of their drugs. Newer developments include
the opportunity to ask drug safety questions electronically in
the Sentinel system, which encompasses up to 100 million
patient records [2]. Nevertheless, pre-marketing and espe-
cially post-marketing drug surveillance may have some
systematic pitfalls. When testing new drugs in phase II and
III studies, all aspects of their desired outcomes are investi-
gated. In order to register adverse drug reactions (ADRs),
some laboratory tests will be conducted and patients are
either screened via a checklist of defined questions, or their
complaints are registered when they are expressed sponta-
neously. If a drug belongs to a certain therapeutic class, its
assumed ADRs are routinely checked. ADRs other than
those that are expected may be discovered by mere chance.
Post-marketing studies are designed to detect rare or late-
emerging ADRs, but they will be performed only to verify
signals of spontaneous reporting systems (SRS). Thus, after
entry to the market (phase IV), no more systematic searches
for ADRs will be made.
Blind spots
Chronic health problems are frequently found in elderly
patients. Therefore, it’s virtually impossible to differentiate
an increased proportion of a certain chronic illness from an
ADR occurring only after years of treatment. For example,
an increased probability of 20 % of diabetes type 2 resulting
in one out of four, instead of one out of five, persons
becoming diabetic during a 10-year treatment of hyperten-
sion with thiazide diuretics would be a relevant health
problem, but could only be detected by systematically
searching for it and not by SRS. Many chronic health distur-
bances are associated with long-term medication. Examples
that are known include: ocular cataracts (steroids), osteoporo-
sis (glitazones), myocardial infarction (non-steroidal anti-
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inflammatory drugs), vitamin B12 deficiency (metformin),
vitamin D deficiency (antiepileptics) and so on.
Practical examples
Recently, we noted that calcium supplements might raise the
risk of myocardial infarction (MI); the association was
detected by chance in two meta-analyses and confirmed in
a large cohort study [3]. An MI in a patient taking supple-
ments for 5–10 years would normally not be attributed to the
long-term use of these bone-protecting pills, and therefore
the association cannot be detected by SRS. Our point is not
whether or not calcium supplements really cause myocardial
infarction [4], but that existing drug surveillance would
probably miss detecting it by SRS. On the other hand,
epidemiological studies not prospectively designed to detect
specific ADRs (here, MI as a function of calcium supplement
intake) can always be criticized, and their results judged to be
inconclusive.
Let us take a look at another example. Last year we
published a review article on osteoporosis in Parkinson’s
disease patients and its possible cause or worsening by
antiparkinsonian treatments [5]. The conclusion was that
there is a strong and reliable association between osteopo-
rosis and either Parkinson’s disease or antiparkinsonian
treatments containing L-dopa.
We contacted the manufacturers of Madopar® and Sine-
met® in order to inform patients that these drugs might be
associated with negative aspects of bone metabolism. But
neither Roche, the MSD companies, nor our Swiss drug
authority (Swissmedic), accepted our suggestion to include
this in the medical consumer information. The reasons were:
a) “We think that Parkinson’s osteoporosis is caused by the
disease itself, or by concomitant sequelae like vitamin D and
protein deficiency and immobility, ” b) “We cannot have
Swiss ‘run alones’ in product information,” and c) “There
are no SRS signals of that coincidence.”
In the case of Parkinson’s osteoporosis, there was no
information set in stone about a causal relationship with L-
dopa. But when warning people of a danger that could be
avoided, does it make a difference whether the obvious red
flag (L-dopa treatment) is the cause, or only a marker of the
imminent damage? We believe that it doesn’t. Are the SRS
reports that are lacking an absolution for L-dopa treatment?
Parkinson’s patients are chronically ill. Damage to bones
will develop over several years. If a patient breaks his hip
after ten years of antiparkinsonian treatment, nobody will
think that this multi-factorial event was caused or worsened
by drug treatment. But this would be the case even if there
was a strong but hidden influence by using drugs containing
L-dopa; and so, the missing SRS notifications are without
any proven value for drug safety.
Indeed, there is a clear metabolic pathway of L-dopa
metabolized to homocysteine (especially in patients with
genetic abnormalit ies like C677T or E1298A of
methylenetetrahydrofolate-reductase, but also in others),
raising serum levels by onefold or twofold over the upper
normal value. And there is clear evidence that very high
homocysteine levels lead to bone loss [6, 7]. But there are
no placebo-controlled randomized studies for this issue,
because it is not ethically feasible to withhold L-dopa from
Parkinson’s patients.
When informing patients and their physicians, drug au-
thorities and companies could contribute to minimizing an
avoidable health problem. For the physicians, there are easy
prevention measures, such as starting treatment with
dopamine-agonists instead L-dopa, avoiding high doses of
L-dopa, early addition of a COMT-inhibitor to L-dopa,
deliberate substitution with vitamins D, B6 and B12 as well
as folic acid, and also blocking bone degradation with a
bisphosphonate or denosumab (although both may also
cause ADRs).
Reasons why things are not changing
Are randomized controlled trials needed in this area [8]? In
the case of L-dopa, there is little hope that trials will be ever
made. For other drugs emerging in the long-term treatment
market, observational studies should be routinely per-
formed, comparing group illness with standardized disease
rates. These studies will not have the same evidence as
randomized controlled trials, but they are the only way to
get information where placebo-controlled trials are not
feasible.
Will treatments which were recently accepted do any
better than L-dopa? Probably not! Rivaroxaban (Xarelto®)
Among the blind,the one-eyed man is king.
Out of sight – out of mind!
Table 1 Factors contributing to under-reporting of ADRs
● high prevalence of the problem, also in patients without
administration of the drug
● insidious, unspectacular appearance of age-related chronic disease
● resulting from the use of “old” drugs
● long-term application
● administration to frail and aged populations [14]
● presence of alternate explications
358 Eur J Clin Pharmacol (2013) 69:357–359
is now registered for anticoagulant treatment in chronic
atrial fibrillation. Solayar et al. published an in vitro study
about depressed osteoblast activity in the presence of
rivaroxaban [9]. Currently no ongoing clinical studies
(ClinicalTrials.gov and as admitted by the Bayer Company)
are investigating bone health in long-term treatment with
rivaroxaban.
“Silent” and multi-factorial health problems evolving in
long-term treatment must be addressed with a systematic
search strategy. Large cohort studies will only detect what is
within the focus of the study. SRS will not help either,
because the coincidences of drug treatment with a given
health disturbance are often not evident to the caregivers.
On average, SRS suffer from overwhelming rates of under-
reporting of 94 % (median value), and selective reporting
also seems to happen frequently [10–12]. Hence, the real
proportion of under-reporting of ADRs could even be
higher. The denominator of the studies was the total of all
“known, suspected or expected” ADRs after tiny controls of
the patient charts; but unsuspected cases of MI during treat-
ment with calcium supplements or hip fractures in patients
taking L-dopa were not counted as ADRs that were missing.
Because of the eminent rates of underreporting, the sus-
pected selective reporting, and the unspectacular appearance
of many ADRs, inferences changing only proportions of
disease rates are seldom detectable by SMRs. We do not
wish to underrate the important contributions of SRS to drug
surveillance [13], but their obvious limitations should be
made evident to every prescriber of drugs.
New focus in pharmacovigilance
In our opinion, there are several factors which favor under-
reporting or selective reporting of ADRs (Table 1). System-
atic reporting may be precluded by a high prevalence of, and
an alternate explication for, an alleged ADR. Therefore,
fractures and osteoporosis should be systematically consid-
ered when introducing a new drug for long-term use to the
market. The latter can easily be monitored by measuring
mineralized bone density, as well as pyridinoline crosslinks,
in urine. Focus should also be on patient survival, heart
attacks and strokes, dementia, diabetes, hypertension, renal
insufficiency, cancer, and macular degeneration. Special
situations continue to be treatment applications for children
and pregnant women.
We need a systematic, observational post-marketing pro-
gram to improve our patchy reporting system to detect
previously unknown ADRs in long-term drug treatment.
Health care professionals should be sensitized to detect
ADRs, and encouraged to report them to their authori-
ties, to uncover serious adverse events and therefore
prevent harming their patients. A lack of opportunity
to perform randomized controlled trials should not be a
reason to allow manufacturers to lose focus on the long-
term safety of their drugs.
It seems that there is a lot of work to do. Let’s get the
focus right!
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